New inhaled drug AGMB-447 tested for lung scarring disease
NCT ID NCT06181370
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an inhaled drug called AGMB-447 in healthy volunteers and people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs. The main goal is to check safety and how the body processes the drug. 143 participants will receive either the drug or a placebo via a nebulizer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AGMB-447 (inhaled drug)
- What this could lead to
- If this early trial shows the drug is safe, it could lead to a new inhaled treatment for idiopathic pulmonary fibrosis, a serious lung disease.
- What could go wrong
- This is a very early Phase 1 study focused on safety, not effectiveness. The drug may not work or could have side effects. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPF are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medicines Evaluation Unit Ltd. an IQVIA business
Manchester, M23 9QZ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a breath test predict lung scarring? new study seeks answers
- New inhaled drug for lung disease tested in healthy people first
- New hope for lung scarring: HSK44459 enters final trial phase
- Healthy volunteers to test experimental lung disease drug
- New drug for lung scarring takes first step in healthy volunteers
- Simple questionnaire could bring palliative care home for lung disease patients